Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cibus, Inc.CLXT · Entity 6658 | Chief Science Officer | January 04, 2021 | January 05, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cibus, Inc.
Report date January 04, 2021 · Filed January 05, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-01-04 transaction · row 1
1 source rowRow 1 · 2021-01-04 · Sale · Disposed 2,513 · Balance 0 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person on December 4, 2020. F2: The price reported in Column 4 is a weighted average. These shares were sold in multiple transactions at prices ranging from $4.05 to $4.25, inclusive. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person on December 4, 2020.
F2: The price reported in Column 4 is a weighted average. These shares were sold in multiple transactions at prices ranging from $4.05 to $4.25, inclusive.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 15, 2018 Filed Jun 15, 2018 22:31 UTC | Cibus, Inc. CLXT · Entity 6658 | SaleCommon Stock | 7,539 | $19.49 | $146,935.11 |
DisclosureSEC source: 0001127602-18-021074 · form4.xml · nonDerivative · entry 1 Voytas Daniel F · CIK 0001712191 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,982 F1 · shares: Represents the sale of shares to Cellectis, S.A. pursuant to a Share Purchase Agreement, dated June 13, 2018, among the reporting person, Cellectis, S.A. and the issuer to cover tax obligations of the reporting person in connection with the vesting on June 14, 2018 of restricted stock units ("RSUs") granted by the issuer to the reporting person. F2 · balance_after: Includes 85,443 RSUs with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and remain unvested; 15,078 shares will vest on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months. Read SEC document |
| May 21, 2018 Filed May 23, 2018 19:16 UTC | Cibus, Inc. CLXT · Entity 6658 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,666 | $0.00 Strike: $3.59 | $0.00 |
DisclosureSEC source: 0001127602-18-018535 · form4.xml · derivative · entry 3 Voytas Daniel F · CIK 0001712191 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 231,002 Underlying: Common Stock · 4,666 shares Expires 2026-04-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The Stock Option was granted on April 7, 2016 and vests 20% on the grant date and 10% on the first anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months (or with an additional 25% vesting immediately if Calyxt, Inc. undergoes a change in control, liquidation, dissolution or initial public offering and the remainder vesting quarterly thereafter). Read SEC document |
| May 21, 2018 Filed May 23, 2018 19:16 UTC | Cibus, Inc. CLXT · Entity 6658 | SaleCommon Stock | 4,666 | $16.63 | $77,589.05 |
DisclosureSEC source: 0001127602-18-018535 · form4.xml · nonDerivative · entry 2 Voytas Daniel F · CIK 0001712191 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,521 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2017. F3 · price: The price reported in Column 4 is weighted average price. These shares were sold in multiple transactions at prices ranging from $16.50-$16.76, inclusive. The reporting person undertakes to provide Calyxt, Inc., any security holder of Calyt, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. F1 · balance_after: Includes 100,521 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and vest 15% on the first anniversary of the grant date and 15% on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months. Read SEC document |
| May 21, 2018 Filed May 23, 2018 19:16 UTC | Cibus, Inc. CLXT · Entity 6658 | Exercise / conversionCommon Stock | 4,666 | $3.59 | $16,750.94 |
DisclosureSEC source: 0001127602-18-018535 · form4.xml · nonDerivative · entry 1 Voytas Daniel F · CIK 0001712191 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,187 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 100,521 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and vest 15% on the first anniversary of the grant date and 15% on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months. Read SEC document |
| May 08, 2018 Filed May 10, 2018 22:09 UTC | Cibus, Inc. CLXT · Entity 6658 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,083 | $0.00 Strike: $3.71 | $0.00 |
DisclosureSEC source: 0001127602-18-017122 · form4.xml · derivative · entry 3 Voytas Daniel F · CIK 0001712191 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,751 Underlying: Common Stock · 4,083 shares Expires 2024-12-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option to purchase shares of Calyxt, Inc. common stock ("Stock Option") was granted on December 3, 2014, and vests 20% on January 3, 2015 and 20% on April 10, 2015, with the remainder vesting quarterly in equal installments over the following three years (or with an additional 25% vesting immediately if Calyxt, Inc. undergoes a change in control, liquidation, dissolution or initial public offering and the remainder vesting quarterly thereafter). Read SEC document |
| May 08, 2018 Filed May 10, 2018 22:09 UTC | Cibus, Inc. CLXT · Entity 6658 | SaleCommon Stock | 4,083 | $15.58 | $63,595.58 |
DisclosureSEC source: 0001127602-18-017122 · form4.xml · nonDerivative · entry 2 Voytas Daniel F · CIK 0001712191 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,521 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2017. F3 · price: The price reported in Column 4 is weighted average price. These shares were sold in multiple transactions at prices ranging from $15.12-$16.15, inclusive. The reporting person undertakes to provide Calyxt, Inc., any security holder of Calyt, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. F1 · balance_after: Includes 100,521 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and vest 15% on the first anniversary of the grant date and 15% on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months. Read SEC document |
| May 08, 2018 Filed May 10, 2018 22:09 UTC | Cibus, Inc. CLXT · Entity 6658 | Exercise / conversionCommon Stock | 4,083 | $3.71 | $15,165.49 |
DisclosureSEC source: 0001127602-18-017122 · form4.xml · nonDerivative · entry 1 Voytas Daniel F · CIK 0001712191 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,604 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 100,521 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and vest 15% on the first anniversary of the grant date and 15% on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months. Read SEC document |
| April 20, 2018 Filed Apr 24, 2018 22:13 UTC | Cibus, Inc. CLXT · Entity 6658 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,666 | $0.00 Strike: $3.59 | $0.00 |
DisclosureSEC source: 0001127602-18-015184 · form4.xml · derivative · entry 3 Voytas Daniel F · CIK 0001712191 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,668 Underlying: Common Stock · 4,666 shares Expires 2026-04-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The Stock Option was granted on April 7, 2016 and vests 20% on the grant date and 10% on the first anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months (or with an additional 25% vesting immediately if Calyxt, Inc. undergoes a change in control, liquidation, dissolution or initial public offering and the remainder vesting quarterly thereafter). Read SEC document |
| April 20, 2018 Filed Apr 24, 2018 22:13 UTC | Cibus, Inc. CLXT · Entity 6658 | SaleCommon Stock | 4,666 | $16.87 | $78,700.96 |
DisclosureSEC source: 0001127602-18-015184 · form4.xml · nonDerivative · entry 2 Voytas Daniel F · CIK 0001712191 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,521 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2017. F3 · price: The price reported in Column 4 is weighted average price. These shares were sold in multiple transactions at prices ranging from $16.7001-$16.92, inclusive. The reporting person undertakes to provide Calyxt, Inc., any security holder of Calyt, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. F1 · balance_after: Includes 100,521 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and vest 15% on the first anniversary of the grant date and 15% on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months. Read SEC document |
| April 20, 2018 Filed Apr 24, 2018 22:13 UTC | Cibus, Inc. CLXT · Entity 6658 | Exercise / conversionCommon Stock | 4,666 | $3.59 | $16,750.94 |
DisclosureSEC source: 0001127602-18-015184 · form4.xml · nonDerivative · entry 1 Voytas Daniel F · CIK 0001712191 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,187 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 100,521 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and vest 15% on the first anniversary of the grant date and 15% on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months. Read SEC document |
| April 09, 2018 Filed Apr 11, 2018 23:47 UTC | Cibus, Inc. CLXT · Entity 6658 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,083 | $0.00 Strike: $3.71 | $0.00 |
DisclosureSEC source: 0001127602-18-014419 · form4.xml · derivative · entry 3 Voytas Daniel F · CIK 0001712191 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,834 Underlying: Common Stock · 4,083 shares Expires 2024-12-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option to purchase shares of Calyxt, Inc. common stock ("Stock Option") was granted on December 3, 2014, and vests 20% on January 3, 2015 and 20% on April 10, 2015, with the remainder vesting quarterly in equal installments over the following three years (or with an additional 25% vesting immediately if Calyxt, Inc. undergoes a change in control, liquidation, dissolution or initial public offering and the remainder vesting quarterly thereafter). Read SEC document |
| April 09, 2018 Filed Apr 11, 2018 23:47 UTC | Cibus, Inc. CLXT · Entity 6658 | SaleCommon Stock | 4,083 | $14.38 | $58,733.55 |
DisclosureSEC source: 0001127602-18-014419 · form4.xml · nonDerivative · entry 2 Voytas Daniel F · CIK 0001712191 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,521 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2017. F3 · price: The price reported in Column 4 is weighted average price. These shares were sold in multiple transactions at prices ranging from $14.04-$14.97, inclusive. The reporting person undertakes to provide Calyxt, Inc., any security holder of Calyt, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. F1 · balance_after: Includes 100,521 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and vest 15% on the first anniversary of the grant date and 15% on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months. Read SEC document |
| April 09, 2018 Filed Apr 11, 2018 23:47 UTC | Cibus, Inc. CLXT · Entity 6658 | Exercise / conversionCommon Stock | 4,083 | $3.71 | $15,165.49 |
DisclosureSEC source: 0001127602-18-014419 · form4.xml · nonDerivative · entry 1 Voytas Daniel F · CIK 0001712191 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,604 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 100,521 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and vest 15% on the first anniversary of the grant date and 15% on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months. Read SEC document |
| March 20, 2018 Filed Mar 22, 2018 23:25 UTC | Cibus, Inc. CLXT · Entity 6658 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,666 | $0.00 Strike: $3.59 | $0.00 |
DisclosureSEC source: 0001127602-18-012594 · form4.xml · derivative · entry 3 Voytas Daniel F · CIK 0001712191 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,334 Underlying: Common Stock · 4,666 shares Expires 2026-04-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The Stock Option was granted on April 7, 2016 and vests 20% on the grant date and 10% on the first anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months (or with an additional 25% vesting immediately if Calyxt, Inc. undergoes a change in control, liquidation, dissolution or initial public offering and the remainder vesting quarterly thereafter). Read SEC document |
| March 20, 2018 Filed Mar 22, 2018 23:25 UTC | Cibus, Inc. CLXT · Entity 6658 | SaleCommon Stock | 4,666 | $17.91 | $83,560.59 |
DisclosureSEC source: 0001127602-18-012594 · form4.xml · nonDerivative · entry 2 Voytas Daniel F · CIK 0001712191 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2017. F2 · price: The price reported in Column 4 is weighted average price. These shares were sold in multiple transactions at prices ranging from $17.50-$18.35, inclusive. The reporting person undertakes to provide Calyxt, Inc., any security holder of Calyt, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| March 20, 2018 Filed Mar 22, 2018 23:25 UTC | Cibus, Inc. CLXT · Entity 6658 | Exercise / conversionCommon Stock | 4,666 | $3.59 | $16,740.67 |
DisclosureSEC source: 0001127602-18-012594 · form4.xml · nonDerivative · entry 1 Voytas Daniel F · CIK 0001712191 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,666 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 08, 2018 Filed Mar 13, 2018 01:49 UTC | Cibus, Inc. CLXT · Entity 6658 | SaleStock Option (Right to Buy) · Derivative | 4,083 | $18.10 Strike: $3.71 | $73,913.73 |
DisclosureSEC source: 0001127602-18-011290 · form4.xml · derivative · entry 1 Voytas Daniel F · CIK 0001712191 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,917 Underlying: Common Stock · 4,083 shares Expires 2024-12-03 F3 · price: The price reported in Column 8 is weighted average price. These shares were sold in multiple transactions at prices ranging from $17.69-$18.50, inclusive. The reporting person undertakes to provide Calyxt, Inc., any security holder of Calyt, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. F1 · derivative.exercise_date: The stock option to purchase shares of Calyxt, Inc. common stock ("Stock Option") was granted on December 3, 2014, and vests 20% on January 3, 2015 and 20% on April 10, 2015, with the remainder vesting quarterly in equal installments over the following three years (or with an additional 25% vesting immediately if Calyxt, Inc. undergoes a change in control, liquidation, dissolution or initial public offering and the remainder vesting quarterly thereafter). F2 · derivative.underlying_shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2017. Read SEC document |
| March 08, 2018 Filed Mar 13, 2018 22:25 UTC Amendment | Cibus, Inc. CLXT · Entity 6658 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,083 | $0.00 Strike: $3.71 | $0.00 |
DisclosureSEC source: 0001127602-18-011460 · form4a.xml · derivative · entry 3 Voytas Daniel F · CIK 0001712191 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,917 Underlying: Common Stock · 4,083 shares Expires 2024-12-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option to purchase shares of Calyxt, Inc. common stock ("Stock Option") was granted on December 3, 2014, and vests 20% on January 3, 2015 and 20% on April 10, 2015, with the remainder vesting quarterly in equal installments over the following three years (or with an additional 25% vesting immediately if Calyxt, Inc. undergoes a change in control, liquidation, dissolution or initial public offering and the remainder vesting quarterly thereafter). Read SEC document |
| March 08, 2018 Filed Mar 13, 2018 22:25 UTC Amendment | Cibus, Inc. CLXT · Entity 6658 | SaleCommon Stock | 4,083 | $18.10 | $73,913.73 |
DisclosureSEC source: 0001127602-18-011460 · form4a.xml · nonDerivative · entry 2 Voytas Daniel F · CIK 0001712191 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2017. F2 · price: The price reported in Column 4 is weighted average price. These shares were sold in multiple transactions at prices ranging from $17.69-$18.50, inclusive. The reporting person undertakes to provide Calyxt, Inc., any security holder of Calyt, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| March 08, 2018 Filed Mar 13, 2018 22:25 UTC Amendment | Cibus, Inc. CLXT · Entity 6658 | Exercise / conversionCommon Stock | 4,083 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-011460 · form4a.xml · nonDerivative · entry 1 Voytas Daniel F · CIK 0001712191 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,083 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.